InfuSystem Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INFU research report →
Range $15 – $15
Price Chart
About the company
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services).
- CEO
- Carrie A. Lachance
- IPO
- 2007
- Employees
- 467
- HQ
- Rochester Hills, MI, US
Get TickerSpark's AI analysis on INFU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $287.48M
- P/E
- 29.90
- Fwd P/E
- 29.09
- PEG
- 0.37
- P/S
- 1.95
- P/B
- 4.38
- EV/EBITDA
- 11.26
- Div Yield
- 0.00%
- Gross Margin
- 57.64%
- Op Margin
- 9.83%
- Net Margin
- 6.54%
- ROE
- 15.77%
- ROIC
- 11.61%
Latest fiscal year · YoY change
- Revenue
- $143.44M+6.4%
- Gross Profit
- $80.30M+14.1%
- Op Income
- $11.92M
- Net Income
- $6.63M+182.6%
- EPS
- $0.32+190.9%
- OCF Growth
- +19.3%
- FCF Growth
- +498.7%
- 52W High
- $15.47
- 52W Low
- $7.29
- 50D MA
- $13.58
- 200D MA
- $10.74
- Beta
- 1.38
- RSI (14)
- 53
- Avg Volume
- 134.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
InfuSystem delivered record Q3 revenue and higher margins, with strong Oncology and Wound Care growth offset by GE contract restructuring and some ERP-related working-capital noise.· November 10, 2026
- Record quarterly revenue of $37.6 million; pro forma revenue growth was 10.2% after the GE Healthcare contract restructuring.
- Adjusted EBITDA margin expanded to 24.9% from 22.8%, with adjusted EBITDA up 12.5% to $9.4 million.
- Wound Care was the standout, up 112% year over year, including about $1.6 million from compression therapy products.
- Oncology remained strong, with revenue up 7.2% and growth driven by volume, reimbursement, and collections.
- Company reaffirmed 2026 guidance: pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low to mid-20% range.
Third quarter revenue increased 3% year over year to $37.6 million; on a pro forma basis, revenue grew 10.2% after adjusting for the GE Healthcare contract restructuring. Gross profit increased 4.4% year over year, and gross margin expanded to 57.8% from 57.1%. Net income was $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11 per diluted share, a year ago. Adjusted EBITDA increased 12.5% to $9.4 million, with adjusted EBITDA margin at 24.9% versus 22.8% last year. For the first nine months of 2026, operating cash flow rose 5% to $18.1 million, and the company ended the quarter with $64.1 million of liquidity and net debt of about $10.6 million, or 0.32x trailing adjusted EBITDA. Management reaffirmed full-year 2026 guidance for pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low to mid-20% range, and said fourth-quarter margins should still fit within that framework despite modest additional investments.
Carrie Lachance framed the quarter as evidence that InfuSystem is executing on a profitable growth strategy, pointing to accelerating pro forma growth each quarter this year and margin expansion. She emphasized that Oncology remains healthy, Wound Care is scaling rapidly, and compression therapy for lymphedema is becoming a more meaningful growth driver. She also highlighted ongoing efforts to improve patient-services economics through workflow automation, software-enabled process improvements, and additional investments planned for Q4.
Barry Steele focused on the mechanics behind the quarter’s profitability and cash generation. He cited gross margin of 57.8%, adjusted EBITDA of $9.4 million, and operating cash flow of $18.1 million year to date, while noting that the company used about $8.7 million for medical equipment and repurchased about $5 million of stock. He also said net debt fell to about $10.6 million, or 0.32x trailing adjusted EBITDA, despite roughly $5 million of temporary working-capital pressure tied to billing and invoicing issues after ERP implementation; he said about $1.3 million of that excess receivable balance had already converted to cash by October.
Analysts pressed on whether Wound Care growth reflected ongoing demand or one-time stocking, and management said it was driven by ongoing new referrals, not pipeline fill. They also asked about ERP-related issues, and management said the earnings delay issue was completely resolved, that collections are improving, and that the company is still working through invoice-format and system stabilization items. On margins, Barry narrowed what he meant by “low to mid-20%” EBITDA margins to roughly 22% to 25%, and management said some new business may carry lower gross margins but should come with faster cash generation and lower processing costs over time.
The call showed strong underlying demand in both Oncology and Wound Care, with Wound Care growing 112% and management saying referral flow remains strong into Q4. Margin gains, improving cash flow, lower net debt, and management’s confidence in ERP-driven efficiency improvements all support the view that InfuSystem can keep scaling profitably. Management also sounded constructive on next-year growth as new systems and workflow changes are expected to support more business and better operating efficiency.
The GE Healthcare restructuring still weighed on reported results, and management noted lower equipment sales and some softer disposable product revenue in Device Solutions. ERP implementation is still creating friction, including billing/invoicing issues and temporary working-capital pressure, and some benefits may not fully show up until next year. Management also acknowledged that some newer business could come with lower gross margins, even if it brings faster cash and lower capital needs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.4%
- Shares Outstanding
- 20.03M
- Float Shares
- 18.91M
of shares held by institutions
103 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.58M | ▼ 8.49K |
| Minerva Advisors LLC | 1.36M | ▲ 14.86K |
| Vanguard Group Inc | 981.58K | ▲ 5.40K |
| American Century Companies Inc | 904.77K | ▲ 229.75K |
| Vanguard Capital Management LLC | 798.82K | ▲ 8.05K |
| Punch & Associates Investment Management, Inc. | 771.89K | ▼ 62.86K |
| Acadian Asset Management LLC | 751.61K | ▲ 8.45K |
| Heartland Advisors Inc | 700.00K | 0 |
| First Eagle Investment Management, LLC | 628.00K | ▲ 8.00K |
| Dimensional Fund Advisors LP | 607.96K | ▲ 8.67K |
| Renaissance Technologies LLC | 496.91K | ▼ 46.10K |
| Geode Capital Management, LLC | 491.11K | ▼ 4.95K |
Held by 133 ETFs
Biggest fund positions in INFU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Lachance Carrie | other | 50,000 |
| Nov 17, 26 | Lachance Carrie | other | 19,675 |
| Oct 9, 26 | Funke Jerod | other | 7,157 |
| Oct 9, 26 | Funke Jerod | other | 2,101 |
| Oct 9, 26 | Funke Jerod | other | 7,157 |
| Sep 10, 26 | Shuda Scott | other | 20,000 |
| May 17, 26 | Steele Barry G | other | 21,323 |
| May 18, 26 | Steele Barry G | other | 8,715 |
| May 18, 26 | Steele Barry G | other | 3,800 |
| May 17, 26 | Steele Barry G | other | 9,297 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INFU coverage
Recent articles, reports, and earnings notes.
No research on INFU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INFU report →InfuSystem: Strong Franchise, Weak Entry Point
seekingalpha.com · Nov 10
InfuSystem Holdings, Inc. (INFU) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
InfuSystem Announces Financial Results for Third Quarter 2026
businesswire.com · Nov 5
InfuSystem (NYSE:INFU) versus Option Care Health (NASDAQ:OPCH) Head to Head Review
defenseworld.net · Nov 4
InfuSystem Announces Change in Third Quarter 2026 Earnings Release Date
businesswire.com · Nov 3
InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026
businesswire.com · Oct 27
InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript
seekingalpha.com · Sep 24
Guardant Health (NASDAQ:GH) versus InfuSystem (NYSE:INFU) Critical Review
defenseworld.net · Sep 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.